AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation.
Rationale : Discontinuing denosumab (Dmab) therapy results in increased bone turnover
and a rapid decrease in bone mineral density (“rebound phenomenon”). To test if the duration
of denosumab treatment affects the efficacy of subsequent zoledronate infusion.
Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4155-e4162.